letter
editor
multiplex
pcr
implement
pointofcar
test
french
emerg
depart
sir
increas
avail
syndrom
test
respiratori
infect
allow
identif
almost
respiratori
virus
bacteria
involv
influenzalik
ill
ili
us
guidelin
specif
recommend
use
influenza
multiplex
polymeras
chain
reaction
mpcr
chang
manag
hospit
patient
patient
benefit
reli
rapid
turnaround
result
regard
sever
kit
suitabl
pointofcar
poc
use
studi
investig
impact
test
antiinfect
prescrib
potenti
costeffect
length
stay
howev
author
knowledg
studi
focus
impact
mpcr
infect
prevent
measur
droplet
precaut
singleroom
alloc
hospit
patient
conduct
prospect
feasibl
studi
use
mpcr
poc
test
emerg
depart
ed
hospit
influenza
epidem
season
impact
mpcr
use
singleroom
assign
antivir
use
among
patient
seek
care
ed
evalu
mpcr
perform
admit
patient
seek
emerg
care
ili
pneumonia
sinc
influenza
season
middecemb
midmarch
rapid
mpcr
method
turnaround
time
min
implement
poc
test
ed
qiastat
dx
panel
qiagen
hilden
germani
seven
emerg
physician
train
perform
mpcr
test
nasopharyng
swab
patient
ili
symptom
triag
level
accord
emerg
sever
index
esi
data
demograph
characterist
level
triag
esi
antibiot
antivir
prescript
ward
admiss
room
assign
collect
prospect
statist
analysi
perform
use
stata
version
stata
corp
colleg
station
tx
usa
research
approv
local
ethic
committe
ceerb
studi
period
patient
ili
test
mpcr
ed
nine
fail
test
exclud
analysi
median
age
includ
patient
year
slightli
men
women
n
posit
rate
mpcr
includ
six
coinfect
influenza
rhinoviru
respiratori
syncyti
viru
rsv
identifi
mpcrposit
sampl
respect
tabl
among
influenzaposit
patient
fever
short
breath
cough
myalgia
present
respect
fever
present
patient
virus
influenza
patient
mpcrneg
signific
differ
symptom
observ
group
thirtyseven
patient
influenzaposit
noninfluenzaposit
neg
mpcr
assign
singl
room
respect
tabl
differ
signific
p
nearli
influenzaposit
patient
receiv
oseltamivir
contrast
six
noninfluenza
patient
p
twenti
influenzaposit
patient
noninfluenza
patient
receiv
empir
antibiot
treatment
p
median
length
stay
patient
posit
mpcr
day
admit
intens
care
unit
eight
die
hospit
stay
without
differ
accord
pathogen
larg
french
ed
use
poc
mpcr
test
strategi
patient
influenza
receiv
appropri
antivir
treatment
nearli
instanc
assign
singl
room
case
well
case
two
sever
virus
rsv
metapneumoviru
previou
retrospect
studi
conduct
studi
ed
show
median
laboratori
mpcr
turnaround
time
h
patient
influenza
appropri
assign
singl
room
nonisol
influenzaposit
patient
singl
room
due
multipl
reason
includ
variabl
epidem
cours
local
avail
room
studi
assess
impact
rapid
turnaround
time
multiplex
test
agre
global
benefit
despit
cost
rang
v
per
unit
recent
studi
england
show
reduct
per
stay
anoth
studi
china
show
reduct
us
per
stay
howev
two
studi
provid
clear
descript
improv
util
isol
facil
among
limit
present
studi
undertaken
singl
centr
limit
number
patient
patient
follow
transfer
clinic
ward
whereupon
impact
mpcr
antibiot
durat
costeffect
could
evalu
howev
high
mpcr
posit
rate
low
failur
rate
point
correct
use
test
rel
small
number
train
ed
physician
high
rate
assign
singl
room
patient
sever
virus
appropri
use
antivir
treatment
strongli
suggest
benefit
poc
mpcr
test
addit
studi
need
confirm
clinic
impact
costeffect
approach
well
benefit
isol
manag
syndrom
test
poc
method
ed
set
none
declar
other
c
icu
intens
care
unit
rsv
respiratori
syncyti
viru
iqr
interquartil
rang
includ
two
codetect
rsv
two
coronaviru
b
includ
one
codetect
rhinoviru
c
includ
two
coronavirus
three
mycoplasma
pneumonia
four
human
metapneumovirus
ed
influenza
manag
studi
group
c
choquet
renoux
v
ing
e
